IN THE NEWS

PRESS RELEASES

IN THE NEWS

08 December 2023

MYC drop: Synthetic lethal drugs are targeting a common cancer culprit

04 April 2023

Anticancer Bioscience – Facilitating Cancer Treatment

11 February 2023

“We need to foster risky projects that can have large rewards”

01 August 2022

From Chengdu To The World: Anticancer Takes Novel Approach To Cancer Drug Development

04 February 2022

Embrace new things and new ideas as curiosity drives creativity and innovation

07 January 2022

Pharma’s Almanac Roundtable: For what therapeutic area do you think we will see the greatest progress in the coming years?

25 October 2021

Anticancer Bioscience: A Precision Therapeutics Company Dedicated to Discovering and Developing Breakthrough Cancer Therapies for Unmet Oncology Needs Around the World

04 September 2021

Treating Cancer with Novel Synthetic Lethal Therapies

23 July 2021

Mini-library approach delivers an arsenal in drug development pipeline

14 July 2021

ACB hires Liu from Eureka Therapeutics to lead push into clinic

14 July 2021

Anticancer Bioscience appoints Dr. Hong Liu, as US-based VP of clinical development

14 June 2021

Anticancer Bioscience: applying synthetic lethality to MYC-driven cancers

07 June 2021

Dun Yang – President & CEO, Anticancer Bioscience

25 March 2021

Synthetic lethal drugs vs. cancer

09 February 2021

China’s Anticancer Bioscience raises $10 million, aims high in China

09 February 2021

Anticancer Bioscience Raises $10M to Advance Synthetic Lethality Programs

08 February 2021

Anticancer Bioscience announces $10 million financing

07 February 2021

A synthetic lethality player emerges in China, armed with lessons on undruggable oncogene from Nobel laureate’s lab